Conversely, cytokine therapy or epigenetic approaches could be developed to derepress LMP1 in order to sensitize latency I tumors such as Burkitt lymphoma to antiviral T-cell surveillance, including adoptive transfer of T-cells reactive with LMP1 derived epitopes [98,99]. The gene discussed is PDLIM7; the disease is Burkitt lymphoma.